Compare Snowflake Inc (SNOW) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Snowflake Inc vs GeneDx Holdings Corp — how do they compare? Snowflake Inc trades at $332 (market cap $118.36B), while GeneDx Holdings Corp trades at $86.53 (market cap $2.56B). The key difference: Snowflake Inc is far larger — about 46.2× GeneDx Holdings Corp's market cap, and Snowflake Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| SNOW | WGS | |
|---|---|---|
Market Cap | $118.36B | $2.56B |
Sector | Technology | Technology |
52-Week High | $356.47 | $167.51 |
52-Week Low | $121.11 | $34.51 |
Enterprise Value | $118.78B | $2.60B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Snowflake (SNOW) trades at $335.50, down 0.5% on the day, following a strong earnings-driven rally. The stock exhibits bullish technical signals with support at $331 and resistance at $340. Revenue growth accelerated to 37% year-over-year in Q2 2026, with consistent earnings beats, though profitability remains negative with a net margin of -20.07%. Recent news highlights AI-driven demand boosting product revenue and customer adoption.
Outlook is positive with 81% analyst buy ratings and a $430.10 price target, reflecting optimism around AI data cloud growth. Key risks include high valuation (P/S 21.25), persistent losses, and competitive pressures. Investors should weigh growth potential against profitability challenges and market volatility.
WGS trades at $85.87, down 0.14% today, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4M, beating estimates, and returned to adjusted profitability early. However, net income remains negative at -$106M for 2026, with high valuation multiples like EV/EBITDA of 161.17. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics.
Outlook is mixed: strong analyst buy consensus (90.9%) and institutional interest support upside, but profitability challenges and a class action lawsuit pose risks. Revenue growth and operational improvements are key catalysts, yet high debt-to-asset ratios and negative margins require monitoring for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Snowflake Inc
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
